Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 43.2% in November

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 8,400 shares, a decrease of 43.2% from the October 31st total of 14,800 shares. Currently, 0.7% of the company’s shares are short sold. Based on an average trading volume of 20,500 shares, the short-interest ratio is presently 0.4 days.

Xenetic Biosciences Trading Up 2.2 %

Shares of NASDAQ:XBIO opened at $4.20 on Friday. The business has a 50-day moving average price of $3.92 and a 200 day moving average price of $3.93. Xenetic Biosciences has a 12-month low of $2.78 and a 12-month high of $5.20. The company has a market capitalization of $6.47 million, a price-to-earnings ratio of -1.55 and a beta of 2.25.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The company had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.75 million. As a group, equities research analysts predict that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a research report on Friday, November 22nd.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.